前哨淋巴结阳性早期乳腺癌患者腋窝淋巴结处理状况分析
杜欢;吴耀禄;
摘要(Abstract)：
腋窝处理对乳腺癌患者主要作用是疾病的分期,随着乳腺癌治疗的进展,腋窝淋巴结的清扫(axillary lymph node dissection,ALND)不再是腋窝的唯一的腋窝处理方式。前哨淋巴结活检(sentinel lymph node biopsy,SLNB)已经成为早期乳腺癌临床腋窝淋巴结阴性患者的标准治疗方式。接受保乳手术满足Z0011试验、IBCSG 23-01入组条件的患者可以不进行ALND,或者考虑腋窝放疗替代ALND。区域淋巴结的放疗也可为患者生存带来益处,应该权衡利弊考虑使用。新辅助治疗前腋窝淋巴结阴性的可在新辅助后行SLNB。新辅助治疗前腋窝淋巴结阳性在新辅助后转为阴性,满足相关条件的也可以考虑SLNB。对新辅助治疗前后腋窝淋巴结都为阳性的,推荐继续使用ALND,不能满足试验标准的仍进行ALND。
关键词(KeyWords)： 前哨淋巴结;乳腺癌;腋窝淋巴结
基金项目(Foundation):
作者(Author): 杜欢;吴耀禄;
Email:
DOI: 10.13799/j.cnki.mdjyxyxb.2020.06.032
参考文献(References)：
- [1] 郭宝良,李挺,刘荫华,等.早期乳腺癌染料法前哨淋巴结活检专家共识及技术操作指南(2018版)[J].中国实用外科杂志,2018,38(8):855-858.
- [2] GIULIANO A E,BALLMAN K V,MCCALL L,et al.Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis:the ACOSOG Z0011 (Alliance) randomized clinical trial[J].JAMA,2017,(8):918-26.
- [3] DONKER M,VAN T,STRAVER MARIEKE E,et al.Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS):a randomized,multicentre,open-label,phase 3 non-inferiority trial[J].Lancet Oncology,2014,(15):1303-1310.
- [4] RUTGERS E J,DONKER M,PONCET C,et al.Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer patients:10 year follow up results of the EORTC AMAROS trial[J].Cancer Research,2019,79(4):156-170.
- [5] GALIMBERTI VA,COLE B F,VIALE G,et al.Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases(IBCSG 23-01):10-year follow-up of a randomised,controlled phase 3 trial[J].Lancet Oncol,2018,(19):1385-1393.
- [6] SOLá M,ALBERRO J A,FRAILE M,et al.Complete axillary lymph node dissection versus clinical follow-up in breast cancer patients with sentinel node micrometastasis:final results from the multicenter clinical trial AATRM 048/13/2000[J].Ann.Surg Oncol,2013,(20):120-127.
- [7] KRAG D N,ANDERSON S J,JULIAN T B,et al.Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer:overall survival findings from the NSABP B-32 randomised phase 3 trial[J].Lancet Oncol,2010,(11):927-933.
- [8] GOYAL A,DODWELL D,POSNOC A.Randomised Trial Looking at Axillary Treatment in Women with One or Two Sentinel Nodes with Macrometastases[J].Clin Oncol (R Coll Radiol),2015,(27):692-695.
- [9] DUANE F K,DODWELL D,CHUA B H.Axillary conservation in women with 1-2 sentinel node-positive breast cancer:Further research is needed[J].J Med Imaging Radiat Oncol,2019,(63):151-153.
- [10] SOUCHON R,SAUTTER B M,SEDLMAYER F,et al.Degro practical guidelines:radiotherapy of breast cancer II:radiotherapy of non-invasive neoplasia of the breast[J].Strahlenther Oncol,2014,(90):8-16.
- [11] TADROS A B,MOO T,STEMPEL M,et al.Axillary management for young women with breast cancer varies between patients electing breast-conservation therapy or mastectomy[J].Breast Cancer Res Treat,2020,(180):197-205.
- [12] MONTERO A,CIéRVIDE R,GARCíA M,et al.Postmastectomy radiation therapy in early breast cancer:Utility or futility?[J].Crit Rev Oncol.Hematol,2020,(147):102887.
- [13] WONG J S,WARREN L E G,BELLON J R.Management of the Regional Lymph Nodes in Early-Stage Breast Cancer[J].Semin Radiat Oncol,2016,(26):37-44.
- [14] BUDACH W,KAMMERS K,BOELKE E,et al.Adjuvant radiotherapy of regional lymph nodes in breast cancer-a meta-analysis of randomized trials[J].Radiat Oncol,2013,(8):267.
- [15] BOUGHEY J C,SUMAN V J,MITTENDORF E A,et al.Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer:the ACOSOG Z1071 (Alliance) clinical trial[J].JAMA,2013,(31):1455-1461.
- [16] KUEHN T,BAUERFEIND I,FEHM T,et al.Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA):a prospective,multicentre cohort study[J].Lancet Oncol,2013,(4):609-618.
- [17] BOILEAU J,POIRIER B,BASIK M,et al.Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer:the SN FNAC stud[J].J Clin Oncol,2015,(33):258-264.
- [18] BOUGHEY J C,SUMAN V J,MITTENDORF A,et al.Factors affecting sentinel lymph node identification rate after neoadjuvant chemotherapy for breast cancer patients enrolled in ACOSOG Z1071 (Alliance)[J].Ann Surg,2015,(26):547-552.
- [19] BOUGHEY J C,BALLMAN V,LE T,et al.Identification and Resection of Clipped Node Decreases the False-negative Rate of Sentinel Lymph Node Surgery in Patients Presenting With Node-positive Breast Cancer (T0-T4,N1-N2) Who Receive Neoadjuvant Chemotherapy:Results From ACOSOG Z1071 (Alliance)[J].Ann Surg,2016,(26):802-807.
- [20] SIMONS J M,KOPPERT L B,LUITEN E J,et al.De-escalation of axillary surgery in breast cancer patients treated in the neoadjuvant setting:a Dutch population-based study[J].Breast Cancer Res Treat,2020,(180):725-733.
- [21] 刘淼,王殊,彭媛,等.ACOSOG Z0011试验标准用于中国前哨淋巴结阳性乳腺癌患者以避免腋窝淋巴结清扫的可行性研究[J].中国癌症杂志,2015,25(2):135-140.